- $797.40m
- $767.39m
- $407.32m
Brief: Leading Proxy Advisory Firms Iss And Glass Lewis Recommend Ardelyx Stockholders Vote In Favor Of Proposed Share Increase
Brief: Ardelyx Announces FDA Acceptance And Six-Month Review For Resubmission Of Its New Drug Application Of XPHOZAH
U.S. RESEARCH ROUNDUP-Builders FirstSource, Weave Communications, Zoominfo Technologies
Ardelyx Inc reports results for the quarter ended in March - Earnings Summary
Brief: Ardelyx Inc Says Company Ends Q1 With Over $130 Million In Cash And Investments
Ardelyx Inc expected to post a loss of 10 cents a share - Earnings Preview
Ardelyx up on resubmission of marketing application for kidney disease drug
Brief: Ardelyx Resubmits New Drug Application To U.S. Food And Drug Administration For Xphozah® (Tenapanor)
Pfizer, hundreds of US drugmakers call for reversal of Texas abortion pill ruling (updated)
US drugmakers call for reversing Texas abortion pill ruling
U.S. STOCKS ON THE MOVE-Altamira, Zscaler, Cooper Companies
Ardelyx soars on upbeat bowel disease drug sales, renal therapy update
U.S. STOCKS ON THE MOVE-Tesla, Meta, Costco, Bumble, Broadcom
U.S. STOCKS ON THE MOVE-Tesla, Broadcom, Gold miners
U.S. STOCKS ON THE MOVE-Costco, Dell Technologies, Veru
Ardelyx rises on upbeat bowel disease drug sales, regulatory update for renal drug
U.S. RESEARCH ROUNDUP-Itron, Marathon Petroleum, Radius Global Infrastructure
Ardelyx Inc reports results for the quarter ended in December - Earnings Summary
Brief: Ardelyx Inc - Resubmission Of Xphozah New Drug Application Expected In Early Q2 2023